Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery

A Hatano, H Takahashi, M Tamaki, T Komeyama, T Koizumi, M Takeda, A Hatano, H Takahashi, M Tamaki, T Komeyama, T Koizumi, M Takeda

Abstract

1. The alpha 1-adrenoceptor subtypes mediating contractions of the smooth muscle in human prostatic urethra and branches of internal iliac artery were characterized in isometric contraction experiments. 2. Phenylephrine produced concentration-dependent contractions in both the urethra and artery. These responses were competitively inhibited by prazosin, WB4101 and 5-methyl-urapidil, and the slopes of Schild plots for all these antagonists were close to unity. 3. The pA2 values for prazosin were not significantly different between the urethra (9.42 +/- 0.11; mean +/- s.d.) and artery (9.50 +/- 0.27), while the pA2 values for WB4101 and 5-methyl-urapidil in the human prostatic urethra (8.94 +/- 0.19 and 8.42 +/- 0.14, respectively) were significantly greater than in the branches of human internal iliac artery (7.94 +/- 0.21 and 7.43 +/- 0.22, respectively; P < 0.01). 4. Pretreatment with chlorethylclonidine (CEC) at concentrations ranging from 0.1 microM to 100 microM attenuated the maximum contraction to phenylephrine in a concentration-dependent manner in both the urethra and artery. However, the urethra was significantly less affected by CEC than the artery. The pD'2 values (negative logarithm of the molar concentration of antagonist which reduced the maximum contraction to one half) in the urethra and artery were 4.35 +/- 0.27 and 5.20 +/- 0.37, respectively (P < 0.01). 5. The present results indicate that there are distinct populations of alpha 1-adrenoceptor subtypes in the human prostatic urethra and branches of the internal iliac artery. The alpha 1-adrenoceptors responsible for the contraction of the human internal iliac artery branches are predominantly alpha 1 B-subtype, whereas those in the human prostatic urethra are considered to be not alpha 1 B, but alpha 1 c or possibly alpha 1 A or alpha 1A/D-subtype.

References

    1. Br J Urol. 1975 Apr;47(2):193-202
    1. Br J Pharmacol Chemother. 1959 Mar;14(1):48-58
    1. J Urol. 1976 May;115(5):545-7
    1. Br J Urol. 1976 Aug;48(4):255-63
    1. Br J Pharmacol. 1980;71(1):5-9
    1. J Urol. 1982 Oct;128(4):836-9
    1. J Urol. 1983 Aug;130(2):275-8
    1. J Urol. 1984 Dec;132(6):1226-9
    1. J Urol. 1985 Aug;134(2):396-8
    1. Mol Pharmacol. 1986 Apr;29(4):321-30
    1. Nature. 1987 Sep 24-30;329(6137):333-5
    1. Mol Pharmacol. 1987 Oct;32(4):505-10
    1. Mol Pharmacol. 1988 May;33(5):509-14
    1. Eur J Pharmacol. 1988 Jul 7;151(2):333-5
    1. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7159-63
    1. J Urol. 1990 Jan;143(1):179-85
    1. J Biol Chem. 1990 May 15;265(14):8183-9
    1. J Urol. 1990 Oct;144(4):908-11; discussion 911-2
    1. J Urol. 1990 Dec;144(6):1393-7; discussion 1397-8
    1. Mol Pharmacol. 1990 Nov;38(5):725-36
    1. Eur J Pharmacol. 1990 Nov 6;190(1-2):97-104
    1. J Biol Chem. 1991 Apr 5;266(10):6365-9
    1. Lancet. 1991 Jun 15;337(8755):1457-61
    1. Mol Pharmacol. 1991 Dec;40(6):876-83
    1. Can J Physiol Pharmacol. 1991 Dec;69(12):1819-24
    1. Eur J Pharmacol. 1992 Dec 1;227(4):433-6
    1. J Urol. 1993 Mar;149(3):640-2
    1. Br J Pharmacol. 1993 May;109(1):80-7
    1. Prostate. 1993;22(4):301-7
    1. J Urol. 1993 Aug;150(2 Pt 1):546-51
    1. Eur J Pharmacol. 1993 Nov 16;249(3):307-15
    1. Arch Int Pharmacodyn Ther. 1957 Apr 1;110(2-3):275-99
    1. J Urol. 1976 Jan;115(1):53-5

Source: PubMed

3
Subskrybuj